Victor J Del Brutto1, David S Liebeskind2, Jose G Romano3, Iszet Campo-Bustillo4, George Cotsonis5, Azhar Nizam6, Shyam Prabhakaran7. 1. Department of Neurology, University of Miami Miller School of Medicine, Miami, FL. Electronic address: vjd30@med.miami.edu. 2. University of California at Los Angeles, Los Angeles, CA. Electronic address: davidliebeskind@yahoo.com. 3. Department of Neurology, University of Miami Miller School of Medicine, Miami, FL. Electronic address: JRomano@med.miami.edu. 4. Department of Neurology, University of Miami Miller School of Medicine, Miami, FL. Electronic address: icampo@med.miami.edu. 5. Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA. Electronic address: gcotson@emory.edu. 6. Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA. Electronic address: anizam@emory.edu. 7. Department of Neurology, The University of Chicago, Chicago, IL. Electronic address: shyam1@neurology.bsd.uchicago.edu.
Abstract
BACKGROUND: The risk of early recurrent cerebral infarction (RCI) is high in patients with symptomatic intracranial atherosclerotic disease (IAD). We sought to determine the relationship between risk factor control and early RCI risk among patients with symptomatic IAD. METHODS: We analyzed participants with symptomatic IAD in the multi-center prospective observational MYRIAD study. Risk factor control was assessed at 6-8-week follow-up. Optimal risk factor control was defined by target systolic blood pressure, being non-smoker, target physical activity, and antiplatelet and antilipidemic therapy compliance. Age-adjusted associations were calculated between risk factor control and RCI determined by MRI-evident new infarcts in the territory of the stenotic vessel at 6-8 weeks from the index event. RESULTS: Among 82 participants with clinical and brain MRI information available 6-8 weeks after the index event (mean age 63.5 ±12.5 years, 62.2% men), RCI occurred in 21 (25.6%) cases. At 6-8-week follow-up, 37.8% had target systolic blood pressure, 92.7% were non-smokers, 51.2% had target physical activity, and 98.8% and 86.6% were compliant with antiplatelet and antilipidemic therapy, respectively. Optimal risk factor control increased from 4.9% at baseline to 19.5% at 6-8-week follow-up (p=0.01). None of the participants with optimal risk factor control at follow-up had RCI (0% vs. 31.8%, p<0.01). CONCLUSIONS: Only one-fifth of MYRIAD participants had optimal risk factor control during early follow-up. Approximately half and two-thirds had physical inactivity and uncontrolled systolic blood pressure, respectively. These risk factors may represent important therapeutic targets to prevent early RCI in patients with symptomatic IAD.
BACKGROUND: The risk of early recurrent cerebral infarction (RCI) is high in patients with symptomatic intracranial atherosclerotic disease (IAD). We sought to determine the relationship between risk factor control and early RCI risk among patients with symptomatic IAD. METHODS: We analyzed participants with symptomatic IAD in the multi-center prospective observational MYRIAD study. Risk factor control was assessed at 6-8-week follow-up. Optimal risk factor control was defined by target systolic blood pressure, being non-smoker, target physical activity, and antiplatelet and antilipidemic therapy compliance. Age-adjusted associations were calculated between risk factor control and RCI determined by MRI-evident new infarcts in the territory of the stenotic vessel at 6-8 weeks from the index event. RESULTS: Among 82 participants with clinical and brain MRI information available 6-8 weeks after the index event (mean age 63.5 ±12.5 years, 62.2% men), RCI occurred in 21 (25.6%) cases. At 6-8-week follow-up, 37.8% had target systolic blood pressure, 92.7% were non-smokers, 51.2% had target physical activity, and 98.8% and 86.6% were compliant with antiplatelet and antilipidemic therapy, respectively. Optimal risk factor control increased from 4.9% at baseline to 19.5% at 6-8-week follow-up (p=0.01). None of the participants with optimal risk factor control at follow-up had RCI (0% vs. 31.8%, p<0.01). CONCLUSIONS: Only one-fifth of MYRIAD participants had optimal risk factor control during early follow-up. Approximately half and two-thirds had physical inactivity and uncontrolled systolic blood pressure, respectively. These risk factors may represent important therapeutic targets to prevent early RCI in patients with symptomatic IAD.
Authors: S Chaturvedi; T N Turan; M J Lynn; S E Kasner; J Romano; G Cotsonis; M Frankel; M I Chimowitz Journal: Neurology Date: 2007-11-27 Impact factor: 9.910
Authors: Mai N Nguyen-Huynh; Max Wintermark; Joey English; Jack Lam; Eric Vittinghoff; Wade S Smith; S Claiborne Johnston Journal: Stroke Date: 2008-02-21 Impact factor: 7.914
Authors: Marc I Chimowitz; Michael J Lynn; Harriet Howlett-Smith; Barney J Stern; Vicki S Hertzberg; Michael R Frankel; Steven R Levine; Seemant Chaturvedi; Scott E Kasner; Curtis G Benesch; Cathy A Sila; Tudor G Jovin; Jose G Romano Journal: N Engl J Med Date: 2005-03-31 Impact factor: 91.245
Authors: Tanya N Turan; Michael J Lynn; Azhar Nizam; Bethany Lane; Brent M Egan; Ngoc-Anh Le; Maria F Lopes-Virella; Kathie L Hermayer; Oscar Benavente; Carole L White; W Virgil Brown; Michelle F Caskey; Meghan R Steiner; Nicole Vilardo; Andrew Stufflebean; Colin P Derdeyn; David Fiorella; Scott Janis; Marc I Chimowitz Journal: Circ Cardiovasc Qual Outcomes Date: 2012-09-01
Authors: E Feldmann; J L Wilterdink; A Kosinski; M Lynn; M I Chimowitz; J Sarafin; H H Smith; F Nichols; J Rogg; H J Cloft; L Wechsler; J Saver; S R Levine; C Tegeler; R Adams; M Sloan Journal: Neurology Date: 2007-04-04 Impact factor: 9.910
Authors: Marc I Chimowitz; Michael J Lynn; Colin P Derdeyn; Tanya N Turan; David Fiorella; Bethany F Lane; L Scott Janis; Helmi L Lutsep; Stanley L Barnwell; Michael F Waters; Brian L Hoh; J Maurice Hourihane; Elad I Levy; Andrei V Alexandrov; Mark R Harrigan; David Chiu; Richard P Klucznik; Joni M Clark; Cameron G McDougall; Mark D Johnson; G Lee Pride; Michel T Torbey; Osama O Zaidat; Zoran Rumboldt; Harry J Cloft Journal: N Engl J Med Date: 2011-09-07 Impact factor: 91.245
Authors: Tanya N Turan; George Cotsonis; Michael J Lynn; Seemant Chaturvedi; Marc Chimowitz Journal: Circulation Date: 2007-05-21 Impact factor: 29.690
Authors: Shyam Prabhakaran; David S Liebeskind; George Cotsonis; Azhar Nizam; Edward Feldmann; Rajbeer S Sangha; Iszet Campo-Bustillo; Jose G Romano Journal: J Stroke Cerebrovasc Dis Date: 2021-10-26 Impact factor: 2.136